Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Nuvalent, Inc. reported that on April 7, 2026 it announced submitting a New Drug Application to the U.S. Food and Drug Administration for neladalkib. The application covers use in tyrosine kinase inhibitor pre-treated, advanced ALK-positive non-small cell lung cancer.
This step moves neladalkib from clinical development into formal regulatory review, an important stage toward potential U.S. market availability if the FDA later approves the drug.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom exercised stock options for 11,430 shares of Class A common stock at an exercise price of $1.08 per share. On the same date, she sold 11,430 shares in open-market transactions at weighted average prices between $103.81 and $106.69.
The filing shows these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating the sales were scheduled in advance. Following the transactions, Balcom directly holds 85,533 shares of Nuvalent Class A common stock.
Nuvalent, Inc. reported that officer Benjamin Lane received new equity-based compensation. On April 1, 2026, Lane was granted a stock option for 19,000 shares of Class A common stock at an exercise price of $105.64 per share, expiring in 2036. He also received 9,500 shares of Class A common stock in the form of restricted stock units, which vest in three equal annual installments starting after April 1, 2026, subject to continued service. Following the RSU grant, Lane directly holds 50,368 shares of Class A common stock.
Nuvalent, Inc. Chief Development Officer Darlene Noci exercised stock options and sold shares in a planned transaction. She exercised options to acquire 5,500 shares of Class A Common Stock at $27.85 per share, then sold 5,500 shares in two open-market trades at weighted average prices of $97.43 and $98.13, all under a Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she directly holds 58,117 shares of Class A Common Stock and 97,829 option shares, indicating she retains a substantial equity stake despite the routine liquidity event.
NUVL notified the sale of 22,000 shares of Class A Common under Rule 144 related to a stock option exercise, to be effected on 03/30/2026 for cash. The filing also lists prior open-market disposals of 4,000, 5,500, and 5,500 shares on 12/30/2025, 01/29/2026, and 02/26/2026, respectively.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options and sold shares in a planned transaction. She exercised options to acquire 5,500 shares of Class A Common Stock at an exercise price of $6.89 per share, from options that are fully vested. On the same date, she sold a total of 5,500 shares in three open-market trades at weighted average prices around $97.50–$99.46 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she directly holds 59,634 shares of Class A Common Stock and retains 83,608 stock options outstanding, according to the filing.
The Vanguard Group filed an amendment to Schedule 13G reporting zero beneficial ownership of Nuvalent Inc. common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The Schedule 13G/A shows 0 shares and 0% ownership and is signed by Ashley Grim on 03/27/2026.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported an exercise-and-sale set of transactions in company stock. On March 24, 2026, she exercised stock options for 11,430 shares of Class A Common Stock at $1.08 per share and sold 11,430 shares that day in open-market trades at weighted-average prices in the mid-$90s. She then sold an additional 13,700 shares on March 25, 2026 at a weighted-average price of $100.16 per share in open-market transactions. All sales were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025. After these transactions, she directly holds 85,533 shares of Nuvalent Class A Common Stock.
NUVL filed a Form 144 notice reporting proposed sales of Class A Common shares. The notice lists multiple lots and dates with specific quantities, including 30,019, 15,701, 4,728 and 8,972 shares tied to option exercises and cash transactions.
The filing identifies transactions dated 03/24/2026 and 12/17/2024 and names J.P. Morgan Securities LLC as an intermediary. The submission is a resale notice of insider-held securities under Form 144.
Nuvalent, Inc. officer Benjamin Lane filed an initial ownership report, listing his equity stake in the company. He directly holds 40,868 shares of Class A Common Stock, along with multiple stock options and restricted stock units that may convert into additional shares over time.
The filing shows stock options over 731, 8,333, 17,848, 15,052, 12,025 and 8,000 shares of Class A Common Stock, with exercise prices from $14.40 to $106.82 and expirations between 2032 and 2036. Footnotes also describe RSUs covering 6,733, 5,200 and 8,000 shares that vest in installments, subject to continued service. The Form 3 reflects holdings rather than new buy or sell transactions.